Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ710MR)

This product GTTS-WQ710MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ710MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1373MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-874
GTTS-WQ5291MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ9544MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA J6M0
GTTS-WQ9674MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ12474MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ9055MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ7156MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ11808MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MK-3475
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW